Luo Yingzhe, Cai Xuebin, Yang Biao, Lu Facheng, Yi Cheng, Wu Guoyu
Department of Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Department of Abdominal Oncology, Division of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Front Oncol. 2024 Aug 26;14:1402837. doi: 10.3389/fonc.2024.1402837. eCollection 2024.
Lymphocyte activation gene 3 (LAG-3), also known as CD223, is an emerging immune checkpoint that follows PD-1 and CTLA-4. Several LAG-3 targeting inhibitors in clinical trials and the combination of relatlimab (anti-LAG-3) and nivolumab (anti-PD-1) have been approved for treating - unresectable or metastatic melanoma. Despite the encouraging clinical potential of LAG-3, the physiological function and mechanism of action in tumors are still not well understood. In this review, we systematically summarized the structure of LAG-3, ligands of LAG-3, cell-specific functions and signaling of LAG-3, and the current status of LAG-3 inhibitors under development.
淋巴细胞激活基因3（LAG-3），也称为CD223，是继程序性死亡受体1（PD-1）和细胞毒性T淋巴细胞相关蛋白4（CTLA-4）之后出现的一种免疫检查点。几种正在进行临床试验的LAG-3靶向抑制剂以及瑞帕利单抗（抗LAG-3）和纳武利尤单抗（抗PD-1）的联合用药已被批准用于治疗不可切除或转移性黑色素瘤。尽管LAG-3具有令人鼓舞的临床潜力，但其在肿瘤中的生理功能和作用机制仍未得到充分了解。在这篇综述中，我们系统地总结了LAG-3的结构、LAG-3的配体、LAG-3的细胞特异性功能和信号传导，以及正在开发的LAG-3抑制剂的现状。
